Cerity Partners LLC Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Cerity Partners LLC boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 93.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 127,071 shares of the company's stock after buying an additional 61,271 shares during the period. Cerity Partners LLC's holdings in Takeda Pharmaceutical were worth $1,807,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Millennium Management LLC boosted its holdings in shares of Takeda Pharmaceutical by 87.1% in the 2nd quarter. Millennium Management LLC now owns 4,346,151 shares of the company's stock valued at $56,239,000 after acquiring an additional 2,023,707 shares during the last quarter. Cowen AND Company LLC acquired a new stake in Takeda Pharmaceutical during the 2nd quarter worth about $6,866,000. Van ECK Associates Corp raised its stake in shares of Takeda Pharmaceutical by 21.1% during the 2nd quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company's stock valued at $26,408,000 after buying an additional 356,069 shares during the last quarter. Manning & Napier Advisors LLC acquired a new position in shares of Takeda Pharmaceutical in the 2nd quarter valued at about $4,098,000. Finally, Hantz Financial Services Inc. purchased a new stake in shares of Takeda Pharmaceutical in the second quarter worth about $2,843,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

TAK stock traded up $0.07 during trading on Tuesday, hitting $13.93. 1,465,901 shares of the company traded hands, compared to its average volume of 1,843,931. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.08. The company has a market cap of $44.31 billion, a PE ratio of 24.01, a P/E/G ratio of 0.25 and a beta of 0.51. The stock's 50-day simple moving average is $13.94 and its 200 day simple moving average is $13.86. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.